Naomi M Simon1, Zandra E Walton2, Eric Bui3, Jennifer Prescott4, Elizabeth Hoge3, Aparna Keshaviah5, Noah Schwarz5, Taylor Dryman5, Rebecca A Ojserkis5, Benjamin Kovachy5, David Mischoulon3, John Worthington3, Immaculata De Vivo6, Maurizio Fava3, Kwok-Kin Wong7. 1. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: nsimon@mgh.harvard.edu. 2. Dana-Farber Cancer Institute, Boston, MA, United States. 3. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. 4. Dana-Farber Cancer Institute, Boston, MA, United States; Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States. 5. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States. 6. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States; Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States. 7. Harvard Medical School, Boston, MA, United States; Dana-Farber Cancer Institute, Boston, MA, United States.
Abstract
BACKGROUND: Leukocyte telomere length (LTL) is a marker of cellular turnover and oxidative stress. Studies suggest major depressive disorder (MDD) is associated with oxidative stress, but examinations of MDD and LTL have yielded mixed results, likely because of differences in measurement methods and unmeasured confounding. This study examined LTL and telomerase activity in 166 individuals with MDD compared to 166 age- and gender-matched matched controls free of any psychiatric disorder, using well-validated assays and clinical assessment methods, and controlling for a range of potential confounders. METHODS: Subjects aged 18 to 70 were evaluated by trained raters and provided blood for LTL and telomerase activity measurement. LTL was assayed using Southern blot and replicated with qPCR, and telomerase activity was assayed with a repeat amplification protocol using a commercial kit. RESULTS: There was no significant difference in telomere length for individuals with MDD [mean (SD)=9.1 (3.0)kbp] compared to controls [mean(SD)=8.9(2.5)kbp] measured by Southern blot (p=0.65) or by confirmatory qPCR (p=0.91) assays. Controlling for potential confounders did not alter the results. Telomerase activity did not differ by MDD diagnosis overall (p=0.40), but the effect of MDD was significantly modified by gender (t(299)=2.67, p=0.0079) even after controlling for potential confounders, with telomerase activity significantly greater only in males with MDD versus controls. CONCLUSION: Our well-characterized, well-powered examination of concurrently assessed telomere length and telomerase activity in individuals with clinically significant, chronic MDD and matched controls failed to provide strong evidence of an association of MDD with shorter LTL, while telomerase activity was higher in men with MDD [corrected].
BACKGROUND: Leukocyte telomere length (LTL) is a marker of cellular turnover and oxidative stress. Studies suggest major depressive disorder (MDD) is associated with oxidative stress, but examinations of MDD and LTL have yielded mixed results, likely because of differences in measurement methods and unmeasured confounding. This study examined LTL and telomerase activity in 166 individuals with MDD compared to 166 age- and gender-matched matched controls free of any psychiatric disorder, using well-validated assays and clinical assessment methods, and controlling for a range of potential confounders. METHODS: Subjects aged 18 to 70 were evaluated by trained raters and provided blood for LTL and telomerase activity measurement. LTL was assayed using Southern blot and replicated with qPCR, and telomerase activity was assayed with a repeat amplification protocol using a commercial kit. RESULTS: There was no significant difference in telomere length for individuals with MDD [mean (SD)=9.1 (3.0)kbp] compared to controls [mean(SD)=8.9(2.5)kbp] measured by Southern blot (p=0.65) or by confirmatory qPCR (p=0.91) assays. Controlling for potential confounders did not alter the results. Telomerase activity did not differ by MDD diagnosis overall (p=0.40), but the effect of MDD was significantly modified by gender (t(299)=2.67, p=0.0079) even after controlling for potential confounders, with telomerase activity significantly greater only in males with MDD versus controls. CONCLUSION: Our well-characterized, well-powered examination of concurrently assessed telomere length and telomerase activity in individuals with clinically significant, chronic MDD and matched controls failed to provide strong evidence of an association of MDD with shorter LTL, while telomerase activity was higher in men with MDD [corrected].
Authors: Michael Maes; Ivana Mihaylova; Marta Kubera; Jean-Claude Leunis; Michel Geffard Journal: J Affect Disord Date: 2011-09-17 Impact factor: 4.839
Authors: Mariuca Vasa-Nicotera; Scott Brouilette; Massimo Mangino; John R Thompson; Peter Braund; Jenny-Rebecca Clemitson; Andrea Mason; Clare L Bodycote; Stuart M Raleigh; Edward Louis; Nilesh J Samani Journal: Am J Hum Genet Date: 2004-11-01 Impact factor: 11.025
Authors: Roxanne Schaakxs; Josine E Verhoeven; Richard C Oude Voshaar; Hannie C Comijs; Brenda W J H Penninx Journal: Am J Geriatr Psychiatry Date: 2014-06-19 Impact factor: 4.105
Authors: I Shalev; T E Moffitt; A W Braithwaite; A Danese; N I Fleming; S Goldman-Mellor; H L Harrington; R M Houts; S Israel; R Poulton; S P Robertson; K Sugden; B Williams; A Caspi Journal: Mol Psychiatry Date: 2014-01-14 Impact factor: 15.992
Authors: Martin Fortin; Catherine Hudon; Marie-France Dubois; José Almirall; Lise Lapointe; Hassan Soubhi Journal: Health Qual Life Outcomes Date: 2005-11-23 Impact factor: 3.186
Authors: Mary C Vance; Eric Bui; Susanne S Hoeppner; Benjamin Kovachy; Jennifer Prescott; David Mischoulon; Zandra E Walton; Melissa Dong; Mireya F Nadal; John J Worthington; Elizabeth A Hoge; Paolo Cassano; Esther H Orr; Maurizio Fava; Immaculata de Vivo; Kwok-Kin Wong; Naomi M Simon Journal: Psychoneuroendocrinology Date: 2018-02-21 Impact factor: 4.905
Authors: Christina M Hough; F Saverio Bersani; Synthia H Mellon; Elissa S Epel; Victor I Reus; Daniel Lindqvist; Jue Lin; Laura Mahan; Rebecca Rosser; Heather Burke; John Coetzee; J Craig Nelson; Elizabeth H Blackburn; Owen M Wolkowitz Journal: Mol Neuropsychiatry Date: 2016-06-22
Authors: Paolo Cassano; Eric Bui; Andrew H Rogers; Zandra E Walton; Rachel Ross; Mary Zeng; Mireya Nadal-Vicens; David Mischoulon; Amanda W Baker; Aparna Keshaviah; John Worthington; Elizabeth A Hoge; Jonathan Alpert; Maurizio Fava; Kwok K Wong; Naomi M Simon Journal: Aust N Z J Psychiatry Date: 2016-09-29 Impact factor: 5.744
Authors: E Vakonaki; K Tsiminikaki; S Plaitis; P Fragkiadaki; D Tsoukalas; I Katsikantami; G Vaki; M N Tzatzarakis; D A Spandidos; A M Tsatsakis Journal: Biomed Rep Date: 2018-01-08